Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.
The Time Has Come for Targeted Therapies for AML: Lights and Shadows / Fiorentini, Alessandro; Capelli, Debora; Saraceni, Francesco; Menotti, Diego; Poloni, Antonella; Olivieri, Attilio. - In: ONCOLOGY AND THERAPY. - ISSN 2366-1070. - 8:1(2020), pp. 13-32. [10.1007/s40487-019-00108-x]
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Alessandro Fiorentini;Francesco Saraceni;Diego Menotti;Antonella Poloni;Attilio Olivieri
Ultimo
2020-01-01
Abstract
Acute myeloid leukemia (AML) is a complex disease characterized by genetic and clinical heterogeneity and high mortality. After 40 years during which the standard of care for patients evolved very little, the therapeutic landscape has recently seen rapid changes, with the approval of eight new drugs by the Food and Drug Administration (FDA) within the last 2 years, providing new opportunities, as well as new challenges, for treating clinicians. These therapies include FLT3 inhibitors midostaurin and gilteritinib, CPX-351 (liposomal cytarabine and daunorubicin), gemtuzumab ozogamicin (GO, anti-CD33 monoclonal antibody conjugated with calicheamicin), IDH1/IDH2 inhibitors ivosidenib and enasidenib, Hedgehog inhibitor glasdegib, and BCL-2 inhibitor venetoclax. In this review, we summarize currently available data on these new drugs and discuss the rapidly evolving therapeutic armamentarium for AML, focusing on targeted therapies.File | Dimensione | Formato | |
---|---|---|---|
Fiorentini_The-time-has-come_VoR_2020.pdf
accesso aperto
Tipologia:
Documento in post-print (versione successiva alla peer review e accettata per la pubblicazione)
Licenza d'uso:
Creative commons
Dimensione
802.13 kB
Formato
Adobe PDF
|
802.13 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.